Core Viewpoint - DexCom (DXCM) is expected to report quarterly earnings of $0.45 per share, reflecting a 4.7% increase year-over-year, with revenues projected at $1.12 billion, indicating an 11.8% year-over-year growth [1]. Financial Estimates - The consensus EPS estimate for the quarter has remained unchanged over the last 30 days, indicating analysts' stable outlook [1]. - Analysts forecast 'Revenue- Hardware' to reach $38.99 million, showing a year-over-year decline of 32% [4]. - 'Revenue- Sensor and other' is projected to be $1.08 billion, suggesting a year-over-year increase of 14.5% [4]. - 'Revenue- United States' is expected to be $809.70 million, reflecting a 10.6% increase from the prior-year quarter [4]. - 'Revenue- International' is likely to reach $311.29 million, indicating a year-over-year growth of 14.3% [5]. Market Performance - Over the past month, DexCom shares have returned +3.1%, compared to the Zacks S&P 500 composite's +4.9% change [5]. - DexCom holds a Zacks Rank 2 (Buy), suggesting it is likely to outperform the overall market in the upcoming period [5].

Core Viewpoint - DexCom, Inc. (DXCM) is expected to report second-quarter 2025 results on July 30, with revenue estimates at $1.12 billion, reflecting an 11.8% year-over-year growth, and earnings per share (EPS) forecasted at 45 cents, indicating a 4.7% increase from the previous year [1][2][6] Group 1: Financial Performance - In the last reported quarter, DexCom's earnings missed estimates by 3.03%, with an average surprise of 0.47% over the past four quarters [1] - The company has seen its shares increase by 11.1% year-to-date, outperforming the industry decline of 10.2% and the S&P 500 Index's increase of 6.9% [1] - DexCom's full-year 2025 revenue guidance is set at $4.6 billion, representing organic growth of 14%, with expected gross and operating margins of approximately 62% and 21%, respectively [10] Group 2: Growth Drivers - Key growth factors for the second quarter include the expansion of the U.S. prescriber base, strong international performance, and the traction of Stelo, an over-the-counter continuous glucose monitor [3][8] - The company's continuous glucose monitoring (CGM) system is now covered by two of the three largest pharmacy benefit managers (PBMs), likely leading to increased adoption [4] - DexCom reported a record number of new patient starts in the past two quarters, indicating improved commercial execution and strong U.S. demand [7] Group 3: International Market Dynamics - The international segment of DexCom showed resilience, growing 7% year-over-year, driven by coverage expansion for type 2 diabetes patients, particularly in Japan and France [7] - The anticipated ramp-up of the G7 CGM and international growth are expected to aid margins in the upcoming quarter [6][10] Group 4: Product Innovations - Stelo is positioned as a significant growth driver for DexCom, targeting individuals with prediabetes and Type 2 diabetes who are not on insulin [8] - The company is enhancing Stelo's adoption through product iterations, awareness campaigns, and new distribution channels, including its launch on Amazon [9]

Live Chat on The Biotech Forum has been dominated by discussion of covered call opportunities in recent quarters. To see what I and the other season biotech investors are targeting as trading ideas in real-time, just initiate your free trial into The Biotech Forum by clicking HERE .Today, I am putting DexCom, Inc. (NASDAQ: DXCM ) in the spotlight. The stock of this medical device concern got a bit of a temporary boost of 10% in late June when the Department of Health and Human Services announced itBret lead ...

Core Viewpoint - DexCom has faced significant challenges in the past year, including a 26% decline in stock price, but it has strong potential for growth in the next five years due to its market position and product offerings [1]. Group 1: Market Opportunity - DexCom specializes in continuous glucose monitoring (CGM) systems, which provide automatic and frequent blood sugar level measurements, leading to better health decisions for diabetes patients [2]. - The company has over 2.5 million customers globally as of 2024, indicating a strong installed base, yet there remains a substantial opportunity for growth in the CGM market [4]. - In the U.S., there are over 4.5 million diabetes patients on insulin therapy who are eligible for CGM but are not currently using it, highlighting a significant untapped market [5]. - The launch of Stelo, an over-the-counter CGM option, has expanded DexCom's addressable market to include diabetes patients not on insulin and those with prediabetes, where CGM penetration is currently low [6]. Group 2: Financial Performance and Valuation - Despite a decline in shares due to lower-than-expected revenue per customer, the company is positioned to improve its financial results as it continues to expand in the CGM market [9]. - DexCom's forward price-to-earnings ratio is 41.5, significantly higher than the healthcare sector average of 15.8, but this is on the lower end compared to its historical averages [10]. - The company has historically maintained high valuation metrics while delivering market-beating returns, suggesting potential for similar performance in the next five to ten years [12]. Group 3: Competitive Landscape and Ecosystem - DexCom competes with Abbott Laboratories in the CGM market, but there is ample opportunity for both companies to succeed given the large global market for CGM technology [12]. - The company benefits from a network effect, as its technology is compatible with various devices and applications, enhancing its ecosystem and attractiveness to developers [13]. - As more compatible technologies are launched, DexCom's appeal to patients is likely to increase, reinforcing its leadership position in the CGM market beyond the next five years [14].

Core Viewpoint - DexCom (DXCM) has been upgraded to a Zacks Rank 1 (Strong Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][2]. Earnings Estimates and Stock Price Movement - The change in a company's future earnings potential, as indicated by earnings estimate revisions, is strongly correlated with near-term stock price movements [3]. - Institutional investors often rely on earnings estimates to calculate the fair value of a company's shares, leading to buying or selling actions that affect stock prices [3]. DexCom's Earnings Outlook - The recent rating upgrade for DexCom reflects an improvement in the company's underlying business, which is expected to positively influence its stock price [4]. - For the fiscal year ending December 2025, DexCom is projected to earn $2.03 per share, with a 0.2% increase in the Zacks Consensus Estimate over the past three months [7]. Zacks Rank System - The Zacks Rank stock-rating system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [6]. - The upgrade of DexCom to a Zacks Rank 1 places it in the top 5% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [9].

Investment Rating - The report maintains a "Buy" rating for Boston Scientific (BSX), Edwards Lifesciences (EW), GE Healthcare (GEHC), Intuitive Surgical (ISRG), and Haemonetics (HAE), while downgrading Tandem Diabetes (TNDM) to "Sell/High Risk" from "Neutral/High Risk" [1][5][20]. Core Insights - The MedTech sector has shown resilience against healthcare headwinds, with a focus on returning to fundamentals and several catalysts expected to drive momentum in the second half of 2025 [1][9]. - The S&P Equipment and Supplies Index has outperformed the broader market, with a year-to-date increase of 7.2%, while relative P/E multiples remain below historical averages [2][12]. - Key upcoming catalysts include product launches and data readouts from various companies, which are anticipated to influence stock performance positively [3][10][11]. Summary by Sections Market Overview - The MedTech industry has largely absorbed tariff impacts, with a weakening USD providing additional support [1][9]. - The S&P 500 is up 6.2% year-to-date, while the S&P Equipment and Supplies Index has increased by 7.2% [2][12]. Company-Specific Insights - Boston Scientific (BSX) is expected to benefit from Farapulse and new product launches, projecting a revenue increase of 80.1% year-over-year in 2Q25 [3][10]. - Edwards Lifesciences (EW) anticipates pivotal data releases and the reopening of TAVR NCD, which could enhance its market position [3][10]. - Intuitive Surgical (ISRG) plans a broad launch of its DV5 system, which is expected to drive stock performance [4][10]. - Haemonetics (HAE) has been upgraded to "Buy" due to improved guidance and revenue growth expectations [5][20]. - Tandem Diabetes (TNDM) faces competitive pressures, leading to its downgrade to "Sell/High Risk" [5][20]. Valuation and Target Prices - Target prices have been adjusted for several companies, with BSX at $125, EW at $95, GEHC at $86, and ISRG at $650 [20][21]. - The report highlights that the relative P/E multiple for the MedTech sector is currently at 1.14x, below historical averages, indicating potential undervaluation [2][12][14].

SAN DIEGO, July 09, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of DexCom, Inc. (NASDAQ: DXCM) for potential breaches of fiduciary duties and violations of the federal securities laws. What is Johnson Fistel Investigating? Between April 28, 2023 and June 5, 2024, certain DexCom insiders caused the company to issue false and misleading public statements regarding its expansion strategy and p ...

Group 1: Novo Nordisk - Novo Nordisk has faced clinical setbacks and unimpressive financial results, leading to significant underperformance in the market over the past 12 months, but the stock now appears attractive [4][9] - The company has strong prospects in the weight management market, with its product Wegovy continuing to grow in sales and awaiting FDA approval for an oral formulation [5][6] - Novo Nordisk is diversifying its pipeline beyond diabetes and obesity, developing treatments for conditions such as hemophilia, Parkinson's disease, and Alzheimer's disease [7] - The company's forward price-to-earnings ratio is 16.8, slightly above the healthcare industry average of 16.3, indicating reasonable valuation [8] - Novo Nordisk has increased its annual dividend per share by nearly 284% over the past decade, with a forward yield of 2.3%, which is above the S&P 500 average of 1.3% [10] Group 2: DexCom - DexCom specializes in continuous glucose monitoring (CGM) systems for diabetics, which provide constant blood sugar level measurements, distinguishing itself from traditional blood glucose meters [11] - The company experienced a slowdown in top-line growth last year due to higher-than-expected rebates in the U.S., but these are considered short-term issues that do not affect long-term prospects [12] - There is significant growth potential in the U.S. market, as many eligible patients have yet to adopt CGM technology, and globally, only a small percentage of diabetics currently use CGM [13][14] - DexCom is expected to benefit from increased insurance coverage for CGM technology, leading to consistent revenue and earnings growth [14][15]

Group 1 - DexCom (DXCM) is outperforming its Medical peers with a year-to-date return of approximately 7.5%, while the average return for Medical companies is -2.9% [4] - DexCom is part of the Medical - Instruments industry, which has an average return of -7.5% this year, indicating that DXCM is performing better within its specific industry [5] - The Zacks Rank for DexCom is 2 (Buy), reflecting a positive earnings outlook with a 0.2% increase in the consensus estimate for full-year earnings over the past 90 days [3] Group 2 - Bayer Aktiengesellschaft (BAYRY) has also outperformed the sector with a year-to-date increase of 59.4% and holds a Zacks Rank of 2 (Buy) [4][5] - The consensus estimate for Bayer's current year EPS has risen by 6.4% over the last three months, indicating improving analyst sentiment [5] - Bayer is part of the Large Cap Pharmaceuticals industry, which is ranked 53 and has seen a slight decline of -0.3% this year [6]

Core Viewpoint - Investors are increasingly seeking growth stocks that demonstrate above-average growth potential, with DexCom (DXCM) being highlighted as a strong candidate due to its favorable growth metrics and Zacks Rank [2][9]. Group 1: Earnings Growth - DexCom has a historical EPS growth rate of 25%, with projected EPS growth of 23.8% for the current year, significantly outperforming the industry average of 14% [4]. - Earnings growth is crucial for investors, as double-digit growth is often seen as indicative of strong future prospects and potential stock price increases [3]. Group 2: Cash Flow Growth - The company currently exhibits a year-over-year cash flow growth of 9.8%, which is notably higher than the industry average of -0.7% [5]. - Over the past 3-5 years, DexCom has achieved an annualized cash flow growth rate of 32%, compared to the industry average of 6.5% [6]. Group 3: Earnings Estimate Revisions - There have been upward revisions in current-year earnings estimates for DexCom, with the Zacks Consensus Estimate increasing by 0.1% over the past month [8]. - Positive trends in earnings estimate revisions are strongly correlated with near-term stock price movements, indicating favorable conditions for DexCom [7]. Group 4: Overall Positioning - DexCom has earned a Growth Score of B and holds a Zacks Rank 2, reflecting its strong growth metrics and positive earnings estimate revisions, positioning it well for potential outperformance in the market [9][10].